Predictors and prevention of diabetic cardiomyopathy

References

• Ashcroft FM Rorsman P Diabetes mellitus and the beta cell: the last ten years Cell 2012 148 6 1160 1171 22424227
   PubMed Web of Science ®Google Scholar
• Goyal BR Mehta AA Diabetic cardiomyopathy: pathophysiological mechanisms and cardiac dysfunction Hum Exp Toxicol Epub November 22, 2012
   Google Scholar
• Poornima IG Parikh P Shannon RP Diabetic cardiomyopathy: the search for a unifying hypothesis Circ Res 2006 98 5 596 605 16543510
   PubMed Web of Science ®Google Scholar
• King H Aubert RE Herman WH Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections Diabetes Care 1998 21 9 1414 1431 9727886
   PubMed Web of Science ®Google Scholar
• Wild S Roglic G Green A Sicree R King H Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 2004 27 5 1047 1053 15111519
   PubMed Web of Science ®Google Scholar
• Mishra PK Singh SR Joshua IG Tyagi SC Stem cells as a therapeutic target for diabetes Front Biosci 2010 15 461 477 20036830
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States 2011 Department of Health and Human Services Atlanta, GA, USA 2011 Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf Accessed March 01, 2012
   Google Scholar
• Tabak AG Herder C Rathmann W Brunner EJ Kivimaki M Prediabetes: a high-risk state for diabetes development Lancet 2012 379 9833 2279 2290 22683128
   PubMed Web of Science ®Google Scholar
• Arora MK Singh UK Molecular mechanisms in the pathogenesis of diabetic nephropathy: An update Vascul Pharmacol Epub January 11, 2013
   Web of Science ®Google Scholar
• Campos C Chronic hyperglycemia and glucose toxicity: pathology and clinical sequelae Postgrad Med 2012 124 6 90 97 23322142
   PubMed Web of Science ®Google Scholar
• Nguyen DV Shaw LC Grant MB Inflammation in the pathogenesis of microvascular complications in diabetes Front Endocrinol (Lausanne) 2012 3 170 23267348
   PubMedGoogle Scholar
• Rahman S Rahman T Ismail AA Rashid AR Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis Diabetes Obes Metab 2007 9 6 767 780 17924861
   PubMed Web of Science ®Google Scholar
• Mathew V Gersh BJ Williams BA Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial Circulation 2004 109 4 476 480 14732749
   PubMed Web of Science ®Google Scholar
• Pignone M Alberts MJ Colwell JA Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Diabetes Care 2010 33 6 1395 1402 20508233
   PubMed Web of Science ®Google Scholar
• Aneja A Tang WH Bansilal S Garcia MJ Farkouh ME Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options Am J Med 2008 121 9 748 757 18724960
   PubMed Web of Science ®Google Scholar
• Maisch B Alter P Pankuweit S Diabetic cardiomyopathy – fact or fiction? Herz 2011 36 2 102 115 21424347
   PubMed Web of Science ®Google Scholar
• Miki T Yuda S Kouzu H Miura T Diabetic cardiomyopathy: pathophysiology and clinical features Heart Fail Rev Epub March 28, 2012
   Web of Science ®Google Scholar
• Sharma V McNeill JH Diabetic cardiomyopathy: where are we 40 years later? Can J Cardiol 2006 22 4 305 308 16568154
   PubMed Web of Science ®Google Scholar
• Tarquini R Lazzeri C Pala L Rotella CM Gensini GF The diabetic cardiomyopathy Acta Diabetol 2011 48 3 173 181 20198391
   PubMed Web of Science ®Google Scholar
• Bloomgarden ZT Glycemic control in diabetes: A tale of three studies Diabetes care 2008 31 1913 1919 18753670
   PubMed Web of Science ®Google Scholar
• Kessler II Mortality experience of diabetic patients. A twenty-six-year follow-up study Am J Med 1971 51 6 715 724 5129542
   PubMed Web of Science ®Google Scholar
• Vihert AM Zhdanov VS Matova EE Atherosclerosis of the aorta and coronary vessels of the heart in cases of various diseases J Atheroscler Res 1969 9 2 179 192 5770400
   PubMedGoogle Scholar
• Ledet T Histological and histochemical changes in the coronary arteries of old diabetic patients Diabetologia 1968 4 5 268 272 4243356
   PubMedGoogle Scholar
• Rubler S Dlugash J Yuceoglu YZ Kumral T Branwood AW Grishman A New type of cardiomyopathy associated with diabetic glomerulosclerosis Am J Cardiol 1972 30 6 595 602 4263660
   PubMed Web of Science ®Google Scholar
• Regan TJ Lyons MM Ahmed SS Evidence for cardiomyopathy in familial diabetes mellitus J Clin Invest 1977 60 4 884 899 893679
   PubMed Web of Science ®Google Scholar
• Fang ZY Prins JB Marwick TH Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications Endocr Rev 2004 25 4 543 567 15294881
   PubMed Web of Science ®Google Scholar
• Elliott P Andersson B Arbustini E Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J 2008 29 2 270 276 17916581
   PubMed Web of Science ®Google Scholar
• Paulus WJ Tschope C Sanderson JE How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology Eur Heart J 2007 28 20 2539 2550 17428822
   PubMed Web of Science ®Google Scholar
• Mishra PK Tyagi N Kumar M Tyagi SC MicroRNAs as a therapeutic target for cardiovascular diseases J Cell Mol Med 2009 13 4 778 789 19320780
   PubMed Web of Science ®Google Scholar
• Tyagi AC Sen U Mishra PK Synergy of microRNA and stem cell: a novel therapeutic approach for diabetes mellitus and cardiovascular diseases Curr Diabetes Rev 2011 7 6 367 376 21864292
   PubMedGoogle Scholar
• Mishra PK Chavali V Metreveli N Tyagi SC Ablation of MMP9 induces survival and differentiation of cardiac stem cells into cardiomyocytes in the heart of diabetics: a role of extracellular matrix Can J Physiol Pharmacol 2012 90 3 353 360 22394373
   PubMed Web of Science ®Google Scholar
• Goodwin GW Taylor CS Taegtmeyer H Regulation of energy metabolism of the heart during acute increase in heart work J Biol Chem 1998 273 45 29530 29539 9792661
   PubMed Web of Science ®Google Scholar
• Depre C Shipley GL Chen W Unloaded heart in vivo replicates fetal gene expression of cardiac hypertrophy Nat Med 1998 4 11 1269 1275 9809550
   PubMed Web of Science ®Google Scholar
• Rodrigues B Cam MC McNeill JH Metabolic disturbances in diabetic cardiomyopathy Mol Cell Biochem 1998 180 1–2 53 57 9546630
   PubMed Web of Science ®Google Scholar
• Belke DD Larsen TS Gibbs EM Severson DL Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice Am J Physiol Endocrinol Metab 2000 279 5 E1104 E1113 11052966
   PubMed Web of Science ®Google Scholar
• Kim JK Kim YJ Fillmore JJ Prevention of fat-induced insulin resistance by salicylate J Clin Invest 2001 108 3 437 446 11489937
   PubMed Web of Science ®Google Scholar
• Schwartzbauer G Robbins J The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival J Biol Chem 2001 276 38 35786 35793 11448956
   PubMed Web of Science ®Google Scholar
• Morisco C Condorelli G Trimarco V Akt mediates the cross-talk between beta-adrenergic and insulin receptors in neonatal cardiomyocytes Circ Res 2005 96 2 180 188 15591229
   PubMed Web of Science ®Google Scholar
• O’Neill BT Abel ED Akt1 in the cardiovascular system: friend or foe? J Clin Invest 2005 115 8 2059 2064 16075047
   PubMed Web of Science ®Google Scholar
• Khamzina L Veilleux A Bergeron S Marette A Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance Endocrinology 2005 146 3 1473 1481 15604215
   PubMed Web of Science ®Google Scholar
• Manning BD Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis J Cell Biol 2004 167 3 399 403 15533996
   PubMed Web of Science ®Google Scholar
• Shah OJ Wang Z Hunter T Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr Biol 2004 14 18 1650 1656 15380067
   PubMed Web of Science ®Google Scholar
• Boudina S Abel ED Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes Physiology (Bethesda) 2006 21 250 258 16868314
   PubMed Web of Science ®Google Scholar
• Eckel J Reinauer H Insulin action on glucose transport in isolated cardiac myocytes: signalling pathways and diabetes-induced alterations Biochem Soc Trans 1990 18 6 1125 1127 1965168
   PubMed Web of Science ®Google Scholar
• Liedtke AJ DeMaison L Eggleston AM Cohen LM Nellis SH Changes in substrate metabolism and effects of excess fatty acids in reperfused myocardium Circ Res 1988 62 3 535 542 3342476
   PubMed Web of Science ®Google Scholar
• Liu GX Hanley PJ Ray J Daut J Long-chain acyl-coenzyme A esters and fatty acids directly link metabolism to K(ATP) channels in the heart Circ Res 2001 88 9 918 924 11349001
   PubMed Web of Science ®Google Scholar
• Abe T Ohga Y Tabayashi N Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats Am J Physiol Heart Circ Physiol 2002 282 1 H138 H148 11748057
   PubMed Web of Science ®Google Scholar
• Malhotra A Sanghi V Regulation of contractile proteins in diabetic heart Cardiovasc Res 1997 34 1 34 40 9217870
   PubMed Web of Science ®Google Scholar
• Takeda N Nakamura I Hatanaka T Ohkubo T Nagano M Myocardial mechanical and myosin isoenzyme alterations in streptozotocin-diabetic rats Jpn Heart J 1988 29 4 455 463 2846906
   PubMedGoogle Scholar
• Du X Matsumura T Edelstein D Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells J Clin Invest 2003 112 7 1049 1057 14523042
   PubMed Web of Science ®Google Scholar
• Nishikawa T Edelstein D Brownlee M The missing link: a single unifying mechanism for diabetic complications Kidney Int Suppl 2000 77 S26 S30 10997687
   PubMed Web of Science ®Google Scholar
• Nishikawa T Edelstein D Du XL Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage Nature 2000 404 6779 787 790 10783895
   PubMed Web of Science ®Google Scholar
• Cai L Kang YJ Oxidative stress and diabetic cardiomyopathy: a brief review Cardiovasc Toxicol 2001 1 3 181 193 12213971
   PubMedGoogle Scholar
• Farhangkhoee H Khan ZA Mukherjee S Heme oxygenase in diabetes-induced oxidative stress in the heart J Mol Cell Cardiol 2003 35 12 1439 1448 14654370
   PubMed Web of Science ®Google Scholar
• Mishra PK Tyagi N Sen U Joshua IG Tyagi SC Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol Cardiovasc Diabetol 2010 9 49 20828387
   PubMed Web of Science ®Google Scholar
• Mishra PK Metreveli N Tyagi SC MMP-9 gene ablation and TIMP-4 mitigate PAR-1-mediated cardiomyocyte dysfunction: a plausible role of dicer and miRNA Cell Biochem Biophys 2010 57 2–3 67 76 20422465
   PubMed Web of Science ®Google Scholar
• Barac A Wang H Shara NM Markers of inflammation, metabolic risk factors, and incident heart failure in American Indians: the Strong Heart Study J Clin Hypertens (Greenwich) 2012 14 1 13 19 22235819
   PubMed Web of Science ®Google Scholar
• Bradham WS Moe G Wendt KA TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling Am J Physiol Heart Circ Physiol 2002 282 4 H1288 H1295 11893563
   PubMed Web of Science ®Google Scholar
• Bradham WS Bozkurt B Gunasinghe H Mann D Spinale FG Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective Cardiovasc Res 2002 53 4 822 830 11922892
   PubMed Web of Science ®Google Scholar
• Calle MC Fernandez ML Inflammation and type 2 diabetes Diabetes Metab 2012 38 3 183 191 22252015
   PubMed Web of Science ®Google Scholar
• Moschos SA Williams AE Perry MM Birrell MA Belvisi MG Lindsay MA Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids BMC Genomics 2007 8 240 17640343
   PubMed Web of Science ®Google Scholar
• Perry MM Moschos SA Williams AE Shepherd NJ Larner-Svensson HM Lindsay MA Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells J Immunol 2008 180 8 5689 5698 18390754
   PubMed Web of Science ®Google Scholar
• Roy S Sen CK MiRNA in innate immune responses: novel players in wound inflammation Physiol Genomics 2011 43 10 557 565 21139022
   PubMed Web of Science ®Google Scholar
• Schaefer JS Montufar-Solis D Vigneswaran N Klein JR Selective upregulation of microRNA expression in peripheral blood leukocytes in IL-10−/− mice precedes expression in the colon J Immunol 2011 187 11 5834 5841 22043014
   PubMed Web of Science ®Google Scholar
• van de Vrie M Heymans S Schroen B MicroRNA involvement in immune activation during heart failure Cardiovasc Drugs Ther 2011 25 2 161 170 21503626
   PubMed Web of Science ®Google Scholar
• Bidasee KR Nallani K Yu Y Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors/calcium-release channels Diabetes 2003 52 7 1825 1836 12829653
   PubMed Web of Science ®Google Scholar
• Candido R Forbes JM Thomas MC A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes Circ Res 2003 92 7 785 792 12623881
   PubMed Web of Science ®Google Scholar
• Cooper ME Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease Am J Hypertens 2004 17 12 Pt 2 31S 38S 15607433
   PubMed Web of Science ®Google Scholar
• Guo M Wu MH Korompai F Yuan SY Upregulation of PKC genes and isozymes in cardiovascular tissues during early stages of experimental diabetes Physiol Genomics 2003 12 2 139 146 12441406
   PubMed Web of Science ®Google Scholar
• Herrmann KL McCulloch AD Omens JH Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy Am J Physiol Heart Circ Physiol 2003 284 4 H1277 H1284 12595292
   PubMed Web of Science ®Google Scholar
• Koya D King GL Protein kinase C activation and the development of diabetic complications Diabetes 1998 47 6 859 866 9604860
   PubMed Web of Science ®Google Scholar
• Wakasaki H Koya D Schoen FJ Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy Proc Natl Acad Sci U S A 1997 94 17 9320 9325 9256480
   PubMed Web of Science ®Google Scholar
• Karayannis G Giamouzis G Cokkinos DV Skoularigis J Triposkiadis F Diabetic cardiovascular autonomic neuropathy: clinical implications Expert Rev Cardiovasc Ther 2012 10 6 747 765 22894631
   PubMedGoogle Scholar
• Lambert GW Straznicky NE Lambert EA Dixon JB Schlaich MP Sympathetic nervous activation in obesity and the metabolic syndrome – causes, consequences and therapeutic implications Pharmacol Ther 2010 126 2 159 172 20171982
   PubMed Web of Science ®Google Scholar
• Mishra PK Givvimani S Metreveli N Tyagi SC Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy Biochem Biophys Res Commun 2010 401 2 175 181 20836991
   PubMed Web of Science ®Google Scholar
• Mishra PK Awe O Metreveli N Qipshidze N Joshua IG Tyagi SC Exercise mitigates homocysteine – beta2-adrenergic receptor interactions to ameliorate contractile dysfunction in diabetes Int J Physiol Pathophysiol Pharmacol 2011 3 2 97 106 21760968
   PubMedGoogle Scholar
• Wang G Zhu X Xie W Rad as a novel regulator of excitation-contraction coupling and beta-adrenergic signaling in heart Circ Res 2010 106 2 317 327 19926875
   PubMed Web of Science ®Google Scholar
• Fowlkes V Clark J Fix C Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts Life Sci Epub January 16, 2013
   Web of Science ®Google Scholar
• Delucchi F Berni R Frati C Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats PLoS One 2012 7 6 e39836 22768138
   PubMed Web of Science ®Google Scholar
• Zou MH Xie Z Regulation of interplay between autophagy and apoptosis in the diabetic heart: New role of AMPK Autophagy Epub February 4, 2013
   Web of Science ®Google Scholar
• Marciano C Galderisi M Gargiulo P Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease Eur J Nucl Med Mol Imaging 2012 39 7 1199 1206 22526959
   PubMed Web of Science ®Google Scholar
• Papa G Degano C Iurato MP Licciardello C Maiorana R Finocchiaro C Macrovascular complication phenotypes in type 2 diabetic patients Cardiovasc Diabetol Epub January 18, 2013
   Web of Science ®Google Scholar
• Wang CC Reusch JE Diabetes and cardiovascular disease: changing the focus from glycemic control to improving long-term survival Am J Cardiol 2012 110 Suppl 9 58B 68B
   Web of Science ®Google Scholar
• Ernande L Thibault H Bergerot C Systolic myocardial dysfunction in patients with type 2 diabetes mellitus: identification at MR imaging with cine displacement encoding with stimulated echoes Radiology 2012 265 2 402 409 22929334
   PubMed Web of Science ®Google Scholar
• Zhang H Zhang Y Li Z Left ventricular radial systolic dysfunction in diabetic patients assessed by myocardial acceleration derived from velocity vector imaging J Ultrasound Med 2012 31 8 1179 1186 22837281
   PubMed Web of Science ®Google Scholar
• Asrih M Steffens S Emerging role of epigenetics and miRNA in diabetic cardiomyopathy Cardiovasc Pathol 2013 22 2 117 125 22951386
   PubMed Web of Science ®Google Scholar
• Boudina S Abel ED Diabetic cardiomyopathy, causes and effects Rev Endocr Metab Disord 2010 11 1 31 39 20180026
   PubMed Web of Science ®Google Scholar
• Boyer JK Thanigaraj S Schechtman KB Perez JE Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus Am J Cardiol 2004 93 7 870 875 15050491
   PubMed Web of Science ®Google Scholar
• Taegtmeyer H Cardiac metabolism as a target for the treatment of heart failure Circulation 2004 110 8 894 896 15326079
   PubMed Web of Science ®Google Scholar
• Cosson S Kevorkian JP Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab 2003 29 5 455 466 14631322
   PubMed Web of Science ®Google Scholar
• Maya L Villarreal FJ Diagnostic approaches for diabetic cardiomyopathy and myocardial fibrosis J Mol Cell Cardiol 2010 48 3 524 529 19595694
   PubMed Web of Science ®Google Scholar
• Murarka S Movahed MR Diabetic cardiomyopathy J Card Fail 2010 16 12 971 979 21111987
   PubMed Web of Science ®Google Scholar
• Achenbach S Ropers D Regenfus M Noninvasive coronary angiography by magnetic resonance imaging, electron-beam computed tomography, and multislice computed tomography Am J Cardiol 2001 88 2A 70E 73E
   Web of Science ®Google Scholar
• Charoenpanichkit C Morgan TM Hamilton CA Left ventricular hypertrophy influences cardiac prognosis in patients undergoing dobutamine cardiac stress testing Circ Cardiovasc Imaging 2010 3 4 392 397 20442370
   PubMed Web of Science ®Google Scholar
• Gebker R Mirelis JG Jahnke C Influence of left ventricular hypertrophy and geometry on diagnostic accuracy of wall motion and perfusion magnetic resonance during dobutamine stress Circ Cardiovasc Imaging 2010 3 5 507 514 20576810
   PubMed Web of Science ®Google Scholar
• Alter P Rupp H Rominger MB B-type natriuretic peptide and wall stress in dilated human heart Mol Cell Biochem 2008 314 1–2 179 191 18461428
   PubMed Web of Science ®Google Scholar
• Alter P Rupp H Maisch B Assessment and relevance of ventricular wall stress in heart failure Eur Heart J 2008 29 18 2316 18621773
   PubMed Web of Science ®Google Scholar
• Alter P Rupp H Rominger MB A new method to assess ventricular wall stress in patients with heart failure and its relation to heart rate variability Int J Cardiol 2010 139 3 301 303 18952305
   PubMed Web of Science ®Google Scholar
• Gottlieb I Macedo R Bluemke DA Lima JA Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives Heart Fail Rev 2006 11 4 313 323 17131077
   PubMed Web of Science ®Google Scholar
• Macedo R Schmidt A Rochitte CE Lima JA Bluemke DA MRI to assess arrhythmia and cardiomyopathies J Magn Reson Imaging 2006 24 6 1197 1206 17083108
   PubMed Web of Science ®Google Scholar
• Jones SP A bittersweet modification: O-GlcNAc and cardiac dysfunction Circ Res 2005 96 9 925 926 15890978
   PubMed Web of Science ®Google Scholar
• Lunde IG Aronsen JM Kvaloy H Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure Physiol Genomics 2012 44 2 162 172 22128088
   PubMed Web of Science ®Google Scholar
• Zachara NE The roles of O-linked beta-N-acetylglucosamine in cardiovascular physiology and disease Am J Physiol Heart Circ Physiol 2012 302 10 H1905 H1918 22287582
   PubMed Web of Science ®Google Scholar
• Bartel DP MicroRNAs: target recognition and regulatory functions Cell 2009 136 2 215 233 19167326
   PubMed Web of Science ®Google Scholar
• Chavali V Tyagi SC Mishra PK MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes Biochem Biophys Res Commun 2012 425 3 668 672 22842467
   PubMed Web of Science ®Google Scholar
• Feng B Chen S George B Feng Q Chakrabarti S miR133a regulates cardiomyocyte hypertrophy in diabetes Diabetes Metab Res Rev 2010 26 1 40 49 20013939
   PubMed Web of Science ®Google Scholar
• Ajit SK Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules Sensors (Basel) 2012 12 3 3359 3369 22737013
   PubMed Web of Science ®Google Scholar
• Dimmeler S Zeiher AM Circulating microRNAs: novel biomarkers for cardiovascular diseases? Eur Heart J 2010 31 22 2705 2707 20605798
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S de RS Fox H Circulating microRNAs in patients with coronary artery disease Circ Res 2010 107 5 677 684 20595655
   PubMed Web of Science ®Google Scholar
• Fichtlscherer S Zeiher AM Dimmeler S Circulating microRNAs: biomarkers or mediators of cardiovascular diseases? Arterioscler Thromb Vasc Biol 2011 31 11 2383 2390 22011751
   PubMed Web of Science ®Google Scholar
• Li C Pei F Zhu X Duan DD Zeng C Circulating microRNAs as novel and sensitive biomarkers of acute myocardial Infarction Clin Biochem 2012 45 10–11 727 732 22713968
   PubMed Web of Science ®Google Scholar
• McManus DD Ambros V Circulating MicroRNAs in cardiovascular disease Circulation 2011 124 18 1908 1910 22042926
   PubMed Web of Science ®Google Scholar
• Scholer N Langer C Kuchenbauer F Circulating microRNAs as biomarkers – True Blood? Genome Med 2011 3 11 72 22112937
   PubMed Web of Science ®Google Scholar
• Tijsen AJ Pinto YM Creemers EE Circulating microRNAs as diagnostic biomarkers for cardiovascular diseases Am J Physiol Heart Circ Physiol 2012 303 9 H1085 H1095 22942181
   PubMed Web of Science ®Google Scholar
• van Empel VP De Windt LJ da Costa Martins PA Circulating miRNAs: reflecting or affecting cardiovascular disease? Curr Hypertens Rep 2012 14 6 498 509 22996205
   PubMed Web of Science ®Google Scholar
• Weiland M Gao XH Zhou L Mi QS Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases RNA Biol 2012 9 6 850 859 22699556
   PubMed Web of Science ®Google Scholar
• Da SD Ausina P Alencar EM Coelho WS Zancan P Sola-Penna M Metformin reverses hexokinase and phosphofructokinase downregulation and intracellular distribution in the heart of diabetic mice IUBMB Life 2012 64 9 766 774 22730258
   PubMed Web of Science ®Google Scholar
• Molavi B Rassouli N Bagwe S Rasouli N A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications Vasc Health Risk Manag 2007 3 6 967 973 18200815
   PubMedGoogle Scholar
• Bellia A Rizza S Galli A Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes Atherosclerosis 2010 210 1 199 201 20018286
   PubMed Web of Science ®Google Scholar
• Lin CL Cheng H Tung CW Simvastatin reverses high glucose-induced apoptosis of mesangial cells via modulation of Wnt signaling pathway Am J Nephrol 2008 28 2 290 297 18004065
   PubMed Web of Science ®Google Scholar
• Ma T Tien L Fang CL Liou YS Jong GP Statins and new-onset diabetes: a retrospective longitudinal cohort study Clin Ther 2012 34 9 1977 1983 22939164
   PubMed Web of Science ®Google Scholar
• Paolisso G Sgambato S De RS Simvastatin reduces plasma lipid levels and improves insulin action in elderly, non-insulin dependent diabetics Eur J Clin Pharmacol 1991 40 1 27 31 2060542
   PubMed Web of Science ®Google Scholar
• Tawfik HE El-Remessy AB Matragoon S Ma G Caldwell RB Caldwell RW Simvastatin improves diabetes-induced coronary endothelial dysfunction J Pharmacol Exp Ther 2006 319 1 386 395 16849625
   PubMed Web of Science ®Google Scholar
• Wei P Grimm PR Settles DC Balwanz CR Padanilam BJ Sansom SC Simvastatin reverses podocyte injury but not mesangial expansion in early stage type 2 diabetes mellitus Ren Fail 2009 31 6 503 513 19839828
   PubMed Web of Science ®Google Scholar
• Yao XM Ye SD Zai Z Simvastatin protects diabetic rats against kidney injury through the suppression of renal matrix metalloproteinase-9 expression J Endocrinol Invest 2010 33 5 292 296 19820293
   PubMed Web of Science ®Google Scholar